Epilepsy Chronic Articles & Analysis
5 news found
The letter recaps the key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond directed at developing the Evo® platform thin film electrode technology for patients suffering from epilepsy, chronic back pain, and Parkinson's disease. In his letter, Dave Rosa, Chief Executive Officer of NeuroOne, states, "As we ...
“About a third of individuals with epilepsy have drug-resistant seizures. Removal or ablation of the affected temporal lobe can be an option, but many people with epilepsy are not eligible or interested in a tissue-destructive procedure. ...
“We are excited to have begun recruiting for the clinical trial and to evaluate the safety and efficacy of NRTX-1001, which has the potential to improve quality of life for people living with drug-resistant focal epilepsy. The data, generated from a single targeted administration in a preclinical model of chronic mesial temporal lobe ...
These results support the potential expansion of utilization of these electrodes for long-term recording for indications such as epilepsy, Parkinson's disease, chronic back pain due to failed back surgeries, other related neurological disorders as well as research applications. ...
Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the safety and efficacy of NRTX-1001 in patients with drug-resistant mesial temporal lobe epilepsy (MTLE). Epilepsy is one of the most common neurological disorders affecting over three million people in the U.S. ...